Allspring Global Investments Holdings LLC Buys 246,049 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Allspring Global Investments Holdings LLC increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 70.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 593,523 shares of the company's stock after purchasing an additional 246,049 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.48% of Vaxcyte worth $49,418,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its holdings in shares of Vaxcyte by 23.1% in the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock valued at $1,247,954,000 after acquiring an additional 2,052,989 shares in the last quarter. RA Capital Management L.P. boosted its stake in Vaxcyte by 5.9% during the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock valued at $992,914,000 after purchasing an additional 485,436 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Vaxcyte by 47.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company's stock valued at $148,075,000 after purchasing an additional 419,600 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Vaxcyte in the 3rd quarter worth $41,114,000. Finally, Franklin Resources Inc. lifted its holdings in shares of Vaxcyte by 13.2% in the third quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock valued at $315,162,000 after buying an additional 324,560 shares during the period. Institutional investors own 96.78% of the company's stock.

Insider Activity

In other news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total transaction of $669,280.00. Following the transaction, the chief operating officer now directly owns 205,695 shares in the company, valued at $17,208,443.70. The trade was a 3.74 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Grant Pickering sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $92.45, for a total value of $1,386,750.00. Following the sale, the chief executive officer now owns 450,301 shares of the company's stock, valued at approximately $41,630,327.45. This represents a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 68,616 shares of company stock worth $6,095,681 in the last 90 days. Company insiders own 3.10% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on PCVX. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Vaxcyte in a report on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $14.00 target price on shares of Vaxcyte in a research note on Tuesday, February 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $127.71.

Vaxcyte Price Performance

Vaxcyte stock traded up $0.16 during mid-day trading on Monday, hitting $84.00. The company's stock had a trading volume of 894,632 shares, compared to its average volume of 1,213,280. Vaxcyte, Inc. has a 52-week low of $58.10 and a 52-week high of $121.06. The company has a market cap of $10.47 billion, a PE ratio of -18.26 and a beta of 0.98. The firm's 50 day moving average is $86.19 and its 200 day moving average is $94.68.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.